BACKGROUND: Depression and anxiety in patients with atrial fibrillation (AF) and/or atrial flutter may influence the effectiveness of cardioversion and ablation. There is a lack of knowledge related to depressive symptoms and anxiety at the time of these procedures. OBJECTIVE: We aimed to describe the prevalence and explore potential covariates of depressive symptoms and anxiety in patients with AF at the time of cardioversion or ablation. We further explored the influence of depressive symptoms and anxiety on quality of life at the time of procedure and 6-month AF recurrence. METHODS: Depressive symptoms, anxiety, and quality of life were collected at the time of cardioversion or ablation using the Patient Health Questionnaire-9, State-Trait Anxiety Inventory, and Atrial Fibrillation Effect on Quality of Life questionnaire. Presence of AF recurrence within 6 months post procedure was evaluated. RESULTS: Participants (N = 171) had a mean (SD) age of 61.20 (11.23) years and were primarily male (80.1%) and white, non-Hispanic (81.4%). Moderate to severe depressive symptoms (17.2%) and clinically significant state (30.2%) and trait (23.6%) anxiety were reported. Mood/anxiety disorder diagnosis was associated with all 3 symptoms. Atrial fibrillation symptom severity was associated with both depressive symptoms and trait anxiety. Heart failure diagnosis and digoxin use were also associated with depressive symptoms. Trends toward significance between state and trait anxiety and participant race/ethnicity as well as depressive symptoms and body mass index were observed. Study findings support associations between symptoms and quality of life, but not 6-month AF recurrence. CONCLUSION: Depressive symptoms and anxiety are common in patients with AF. Healthcare providers should monitor patients with AF for depressive symptoms and anxiety at the time of procedures and intervene when indicated. Additional investigations on assessment, prediction, treatment, and outcome of depressive symptoms and anxiety in patients with AF are warranted.
BACKGROUND: Depression and anxiety in patients with atrial fibrillation (AF) and/or atrial flutter may influence the effectiveness of cardioversion and ablation. There is a lack of knowledge related to depressive symptoms and anxiety at the time of these procedures. OBJECTIVE: We aimed to describe the prevalence and explore potential covariates of depressive symptoms and anxiety in patients with AF at the time of cardioversion or ablation. We further explored the influence of depressive symptoms and anxiety on quality of life at the time of procedure and 6-month AF recurrence. METHODS: Depressive symptoms, anxiety, and quality of life were collected at the time of cardioversion or ablation using the Patient Health Questionnaire-9, State-Trait Anxiety Inventory, and Atrial Fibrillation Effect on Quality of Life questionnaire. Presence of AF recurrence within 6 months post procedure was evaluated. RESULTS: Participants (N = 171) had a mean (SD) age of 61.20 (11.23) years and were primarily male (80.1%) and white, non-Hispanic (81.4%). Moderate to severe depressive symptoms (17.2%) and clinically significant state (30.2%) and trait (23.6%) anxiety were reported. Mood/anxiety disorder diagnosis was associated with all 3 symptoms. Atrial fibrillation symptom severity was associated with both depressive symptoms and trait anxiety. Heart failure diagnosis and digoxin use were also associated with depressive symptoms. Trends toward significance between state and trait anxiety and participant race/ethnicity as well as depressive symptoms and body mass index were observed. Study findings support associations between symptoms and quality of life, but not 6-month AF recurrence. CONCLUSION: Depressive symptoms and anxiety are common in patients with AF. Healthcare providers should monitor patients with AF for depressive symptoms and anxiety at the time of procedures and intervene when indicated. Additional investigations on assessment, prediction, treatment, and outcome of depressive symptoms and anxiety in patients with AF are warranted.
Authors: Alexander von Eisenhart Rothe; Frederick Hutt; Jens Baumert; Günther Breithardt; Andreas Goette; Paulus Kirchhof; Karl-Heinz Ladwig Journal: Europace Date: 2015-03-29 Impact factor: 5.214
Authors: G Addolorato; C Ancona; E Capristo; R Graziosetto; L Di Rienzo; M Maurizi; G Gasbarrini Journal: J Psychosom Res Date: 1999-03 Impact factor: 3.006
Authors: Paul Dorian; Miney Paquette; David Newman; Martin Green; Stuart J Connolly; Mario Talajic; Denis Roy Journal: Am Heart J Date: 2002-06 Impact factor: 4.749
Authors: Maria Polikandrioti; Ioannis Koutelekos; Georgios Vasilopoulos; Georgia Gerogianni; Maritsa Gourni; Sofia Zyga; George Panoutsopoulos Journal: Cardiol Res Pract Date: 2018-02-19 Impact factor: 1.866
Authors: Renate B Schnabel; Matthias Michal; Sandra Wilde; Jörg Wiltink; Philipp S Wild; Christoph R Sinning; Edith Lubos; Francisco M Ojeda; Tanja Zeller; Thomas Munzel; Stefan Blankenberg; Manfred E Beutel Journal: PLoS One Date: 2013-12-04 Impact factor: 3.240
Authors: Tomos E Walters; Kate Wick; Gabriel Tan; Megan Mearns; Stephen A Joseph; Joseph B Morton; Prashanthan Sanders; Christina Bryant; Peter M Kistler; Jonathan M Kalman Journal: J Am Heart Assoc Date: 2018-09-18 Impact factor: 5.501
Authors: Isaac L Goldenthal; Robert R Sciacca; Teresa Riga; Suzanne Bakken; Maurita Baumeister; Angelo B Biviano; Jose M Dizon; Daniel Wang; Ketty C Wang; William Whang; Kathleen T Hickey; Hasan Garan Journal: J Cardiovasc Electrophysiol Date: 2019-09-25
Authors: Valérie Pavlicek; Sonja Maria Wedegärtner; Dominic Millenaar; Jan Wintrich; Michael Böhm; Ingrid Kindermann; Christian Ukena Journal: J Clin Med Date: 2022-03-22 Impact factor: 4.241